

11-29-00

#2/A

A

11/28/00
JC820 U.S. PTO

Please type a plus sign (+) inside this box ☐

Attorney Docket P1071P1D3
PATENT

JC843 U.S. PTO
09/724157
11/28/00

CERTIFICATION UNDER 37 CFR 1.10

EL 599 583 952 US: Express Mail Number

November 28, 2000: Date of Deposit

I hereby certify that this Non-provisional Application Transmittal and the documents referred to as enclosed therein are being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.10 on the date indicated above and is addressed to the Assistant Commissioner of Patents, Washington, D.C. 20231.

Pamela Gavette
Pamela Gavette

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

BOX PATENT APPLICATION
Assistant Commissioner of Patents
Washington, D.C. 20231

NON-PROVISIONAL APPLICATION TRANSMITTAL UNDER 37 CFR 1.53(b)

Transmitted herewith for filing is a non-provisional patent application:

Inventor(s) (or Application "Identifier"):

Ross G. Clark, Auckland, New Zealand
Henry B. Lowman, El Granada, California
Iain C.A.F. Robinson, Hertfordshire, Great Britain

Title: INSULIN-LIKE GROWTH FACTOR AGONIST MOLECULES

1. Type of Application

- ☐ This application is for an original, non-provisional application.
- ☐ This is a non-provisional application claiming priority to provisional application no. __, filed __, the entire disclosure of which is hereby incorporated by reference.
- ☒ This is a ☐ continuation-in-part ☐ continuation ☒ divisional application claiming priority to application Serial Number 09/052,888, filed March 31, 1998, which is a continuation-in-part to application no. 08/825,852, filed on April 4, 1997 the entire disclosure of which is hereby incorporated by reference.

2. Papers Enclosed Which Are Required For Filing Date Under 37 CFR 1.53(b)
(Non-provisional)

150 pages of specification
1 pages of claims
1 page(s) of abstract
49 sheet(s) of drawings
☒ formal ☐ informal
40 pages of sequence listing

09/724157 11/28/00

Q

3. Declaration or Oath

(for new and CIP applications; also for Cont./Div. where inventor(s) are being added)

___ An executed declaration of the inventor(s) [] is enclosed [] will follow.

(for Cont./Div. where inventorship is the same or inventor(s) being deleted)

x A copy of the executed declaration/oath filed in the prior application is enclosed (37 CFR 1.63(d)).

(for Cont./Div. where inventor(s) being deleted)

___ A signed statement is attached deleting inventor(s) named in the prior application (see 37 CFR 1.63(d)(2) and 1.33(b)).

4. Assignment

(for new and CIP applications)

___ An Assignment of the invention to GENENTECH, INC. [] is enclosed with attached Recordation Form Cover Sheet [] will follow.

(for cont./div.)

x The prior application is assigned of record to Genentech, Inc.

5. Amendments (for continuation and divisional applications)

___ Cancel in this application original claims __ of the prior application before calculating the filing fee. (At least one original independent claim must be retained for filing purposes.)

___ A preliminary amendment is enclosed. (Claims added by this amendment have been properly numbered consecutively beginning with the number next following the highest numbered original claim in the prior application.)

Relate Back -- 35 U.S.C. 120 or 35 U.S.C. 119

X Amend the specification by deleting the first sentence and replacing it with:

--This is a

___ non-provisional application

___ continuation

x divisional

___ continuation-in-part

of co-pending application(s)

x Serial No. 09/052,888 filed on March 31, 1998, which ^{is a cip} ~~claims priority~~ to application no. 08/825,852, filed on April 4, 1997, which issued as U.S. Pat. No. 6,121,416, which applications are incorporated herein by reference and to which application(s) priority is claimed under 35 USC §120. --

___ International Application _ filed on _ which designated the U.S., which application(s) is(are)

193

a

incorporated herein by reference and to which application(s) priority is claimed under 35 USC §120.--

_____ provisional application No. _ filed __, the entire disclosure of which is hereby incorporated by reference and to which application(s) priority is claimed under 35 USC §119.--.

6. Fee Calculation (37 CFR 1.16)

The fee has been calculated as follows:

CLAIMS FOR FEE CALCULATION					
Number Filed		Number Extra		Rate	Basic Fee 37 CFR 1.16(a)
					\$710.00
Total Claims	7	- 20 =	0	X \$18.00	\$0.00
Independent Claims	1	- 3 =	0	X \$80.00	\$0.00
_____ Multiple dependent claim(s), if any				+ \$270.00	\$0.00
Filing Fee Calculation					\$710.00

7. Method of Payment of Fees

The Commissioner is hereby authorized to charge Deposit Account No. 07-0630 in the amount of \$710.00. **A duplicate copy of this transmittal is enclosed.**

8. Authorization to Charge Additional Fees

The Commissioner is hereby authorized to charge any additional fees required under 37 CFR §1.16 and 1.17, or credit overpayment to Deposit Account No. 07-0630. **A duplicate copy of this sheet is enclosed.**

9. Additional Papers Enclosed

- ☐ Information Disclosure Statement (37 CFR §1.98) w/ PTO-1449 and citations
☒ Letter and Request to Use Computer Readable Sequence.
☐ A new Power of Attorney or authorization of agent.
☐ Other:

10. Maintenance of Copendency of Prior Application (for continuation and divisional applications)

*[This item **must** be completed and the necessary papers filed in the prior application if the period set in the prior application has run]*

- _____ A petition, fee and/or response has been filed to extend the term in the pending prior application until
 _____ A copy of the petition for extension of time in the **prior** application is attached.

11. Correspondence Address:

X Address all future communications to:

Attn: Janet E. Hasak

Respectfully submitted,
GENENTECH, INC.

Date: November 28, 2000

By: Janet E. Hasak
Janet E. Hasak
Reg. No. 28,616
Telephone No. (650) 225-1896



09157

PATENT TRADEMARK OFFICE

Q

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of Ross G. Clark, et al. Serial No.: not yet assigned Filed: November 28, 2000 For: INSULIN-LIKE GROWTH FACTOR AGONIST MOLECULES	Group Art Unit: not yet assigned Examiner: not yet assigned CERTIFICATE OF EXPRESS MAILING I hereby certify that this correspondence is being deposited with the United States Postal Service "Post Office to Addressee" under 37 CFR 1.10 on the date indicated below and is addressed to: Assistant Commissioner of Patents, Washington, D.C. 20231. Express Mail Label No. EL 599 584 122 US November 28, 2000 <i>Pamela Gavette</i> Pamela Gavette
---	---

Letter and REQUEST TO USE COMPUTER-READABLE SEQUENCE LISTINGUNDER 37 CFR §1.821(e)

Assistant Commissioner of Patents
Washington, D.C. 20231

Sir:

Applicants respectfully request that the compliant computer-readable Sequence Listing filed in application Serial No. 09/052,888 be used as the computer-readable Sequence Listing for the present, above-identified application.

The paper copy of the Sequence Listing filed in the present application is identical to the computer-readable copy of the Sequence Listing filed in the application Serial No. 09/052,888.

Respectfully submitted,
GENENTECH, INC.

Date: November 28, 2000

By: *Janet E. Hasak*
Janet E. Hasak
Reg. No. 28,616
Telephone No. (650) 225-1896



09157

PATENT TRADEMARK OFFICE